<a href="https://www.fiercebiotech.com/biotech/incytes-jak-inhibitor-scores-phase-3-vitiligo-wins-cant-quite-shake-rinvoq" hreflang="en">Incyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off Rinvoq</a>
Incyte's JAK inhibitor, povorcitinib, achieved positive results in two phase 3 trials for treating vitiligo, meeting primary endpoints, but analysts noted it did not surpass the efficacy of AbbVie's Rinvoq. Incyte plans to use this data for regulatory approval in 2027, while also pursuing approvals for other conditions.
Incyte's recent phase 3 trials for povorcitinib, an oral JAK inhibitor targeting vitiligo, showed statistically significant improvements, supporting their regulatory approval push. However, the efficacy results slightly lag behind AbbVie's Rinvoq, which could impact competitive positioning. For a healthtech professional, this signifies a critical moment to monitor Incyte's strategy and regulatory progress as they aim to expand their dermatological treatment portfolio, particularly with potential approvals for multiple conditions on the horizon.